A clinical trial to look at how safe risdiplam is and how well risdiplam is processed by the body in healthy volunteers. The trial will also test how risdiplam affects the way that the body processes midazolam.

A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants

  • Muscle And Peripheral Nerve Disease
  • Spinal Muscular Atrophy (SMA)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Country
  • United States
Trial Identifier:

NCT03988907 BP41361

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This will be a Phase I, 2-part, open-label, non-randomized study to investigate the safety, tolerability, and pharmacokinetics (PK) of a multiple-dosing regimen of risdiplam (Part 1) and the effect of risdiplam on the PK of midazolam (Part 2) following oral administration in healthy adult male and female participants.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT03988907, BP41361 Trial Identifier
      All Gender
      ≥18 Years & ≤ 55 Years Age
      Accepts Healthy Volunteers Healthy Volunteers

      How does the BP41361 clinical trial work?

      This clinical trial is recruiting healthy volunteers.

      The purpose of this clinical trial is to test the safety of risdiplam and to understand the way your body processes risdiplam. It will also test whether risdiplam affects the way your body processes another drug called midazolam.

      How do I take part in this clinical trial?
      To be able to take part in this clinical trial, you must be aged between 18 and 55 and be classed as healthy by the clinical study doctors.

      You must not have taken part in any other clinical trials within the last 3 months and you will not be able to take part in the trial if you are a woman who is able to have children.

      If you think this clinical trial may be suitable for you and would like to take part, please talk to your doctor. If your doctor thinks that you might be able to take part in this clinical trial, he/she may refer you to the closest clinical trial doctor. They will give you all the information you need to make your decision about taking part in the clinical trial. You can also find the clinical trial locations on this page.

      You will have some further tests to make sure you will be able to take the treatments given in this clinical trial.

      Before starting the clinical trial, you will be told about any risks and benefits of taking part in the trial.

      While taking part in the clinical trial, men will need to either not have heterosexual intercourse or take contraceptive medication for safety reasons.

      What treatment will I be given if I join this clinical trial?
      The clinical trial will be split into 2 parts. If you join Part 1 of the clinical trial, you will not be able to join Part 2.

      Part 1
      The purpose of Part 1 will be to confirm that risdiplam is safe and confirm the best dose of risdiplam. Everyone who joins Part 1 will be given risdiplam as a liquid to drink every day for 14 days.

      If you join Part 1, you will have to stay in the clinic for 18 days and then visit the clinic 2 days and 4 days after you finish your stay.

      Once risdiplam has been confirmed as safe and the best dose has been selected based on the data from Part 1, the trial will move on to Part 2.

      Part 2
      Part 2 will test whether risdiplam affects how the body processes midazolam. Everyone who joins Part 2 will be given risdiplam as a liquid to drink every day for 14 days (starting on Day 5 of your clinic stay) and midazolam as liquid to drink on Day 3 and Day 17 of your clinic stay.

      If you join Part 2, you will have to stay in the clinic for 20 days and then visit the clinic 2 days and 4 days after you finish your stay.

      How often will I be seen in follow-up appointments, and for how long?
      You will be given the clinical trial treatment risdiplam OR risdiplam and midazolam for about 2 weeks. You are free to stop this treatment at any time. You will be seen by the clinical trial doctor 10 days after your last treatment. This is to see how you are responding to the treatment and any side effects that you may be having.

      What happens if i am unable to take part in this clinical trial?
      If this clinical trial is not suitable for you, you will not be able to take part.

      For more information about this clinical trial see the For Expert tab on the specific ForPatient page or follow this link to ClinicalTrials.gov

      Trial-identifier: NCT03988907

      Trial Summary

      This will be a Phase I, 2-part, open-label, non-randomized study to investigate the safety, tolerability, and pharmacokinetics (PK) of a multiple-dosing regimen of risdiplam (Part 1) and the effect of risdiplam on the PK of midazolam (Part 2) following oral administration in healthy adult male and female participants.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT03988907, BP41361 Trial Identifier
      Risdiplam, Midazolam Treatments
      Spinal Muscular Atrophy Condition
      Official Title

      A Phase I, 2-Part, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Risdiplam and the Effect of Risdiplam on the Pharmacokinetics of Midazolam Following Oral Administration in Healthy Participants

      Eligibility Criteria

      All Gender
      ≥18 Years & ≤ 55 Years Age
      Accepts Healthy Volunteers Healthy Volunteers
      Inclusion Criteria
      • Healthy participants as defined by the Investigator
      • A body mass index (BMI) of 18.0 to 32.0 kg/m2
      • Use of adequate contraception methods during the treatment period and until 4 months after last study drug administration. Males must refrain from donating sperm during this same period
      • Willingness and ability to complete all aspects of the study
      Exclusion Criteria
      • Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study
      • History or evidence of any medical condition potentially altering the absorption, metabolism, or elimination of drugs
      • Surgical history of the GI tract affecting gastric motility or altering the GI tract
      • History or presence of clinically significant ECG abnormalities or cardiovascular disease
      • History of malignancy in the past 5 years
      • Positive result on human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B virus, or hepatitis C virus
      • Donation of blood or blood products for transfusion
      • Participation in an investigational drug medicinal product or medical device study within 90 days prior to Screening
      • Any clinically significant history of hypersensitivity or allergic reactions
      • History of hypersensitivity to midazolam or any other benzodiazepine or its formulation ingredients

      For Part 2 participants:

      • History of acute angle glaucoma

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on ForPatients in related disease areas.

      Spinal Muscular Atrophy (SMA)

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now